1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
Nippon Shinyaku said on January 30 that its lawsuit with Sarepta Therapeutics in Japan over the Duchenne muscular dystrophy (DMD) treatment Viltepso (viltolarsen) has been terminated after the US biotech waived its patent infringement claim.The lawsuit had been filed by…
To read the full story
Related Article
- Nippon Shinyaku’s Viltepso Patents Invalid: US Jury Verdict
December 24, 2024
- Nippon Shinyaku Sues Sarepta over DMD Therapy Patents in US
July 15, 2021
BUSINESS
- FRONTEO to Provide AI-Based Drug Discovery Support Service in US
February 28, 2025
- AstraZeneca Rolling Out “Unify” App for Decentralized Trials in Japan
February 27, 2025
- Daiichi Eyes 9 New Indications for 2 Lead ADCs, Tripling Patient Number by 2026
February 27, 2025
- Kissei Files Linzagolix for Uterine Fibroids in Japan
February 27, 2025
- Lilly Japan Fostering Better Understanding of Health Issues to Retain Female Reps
February 26, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…